Cite
HARVARD Citation
Petrylak, D. et al. (n.d.). 865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Annals of oncology. p. . [Online].